This press release from Atossa Therapeutics discusses positive developments related to their (Z)-endoxifen program, specifically focusing on the safety, tolerability, and efficacy of (Z)-endoxifen as a breast cancer prevention and treatment agent. The company also highlights potential indications they may pursue for (Z)-endoxifen, the expected design and enrollment of trials, and the market opportunities for […]
Category: Biopharmaceuticals in Oncology
Biopharmaceuticals and Monoclonal Antibodies in Oncology Trials
Cancer trials comprise a significant portion of all trials registered, highlighting the overrepresentation of cancer compared to global disease burden. The prevalence of cancer trials can be attributed to extensive pre-clinical research efforts and market forces driving pharmaceutical development, particularly in western countries. This research has enhanced our knowledge of extracellular molecules involved in tumor […]
